These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6365785)

  • 1. Binding of cryptococcal polysaccharide to Cryptococcus neoformans.
    Kozel TR; Hermerath CA
    Infect Immun; 1984 Mar; 43(3):879-86. PubMed ID: 6365785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide.
    Kozel TR
    Infect Immun; 1977 Apr; 16(1):99-106. PubMed ID: 326680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide.
    McGaw TG; Kozel TR
    Infect Immun; 1979 Jul; 25(1):262-7. PubMed ID: 383615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
    Kozel TR; Follette JL
    Infect Immun; 1981 Mar; 31(3):978-84. PubMed ID: 7014468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.
    Kozel TR; Reiss E; Cherniak R
    Infect Immun; 1980 Aug; 29(2):295-300. PubMed ID: 7011970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
    Kozel TR; Gotschlich EC
    J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.
    Small JM; Mitchell TG
    Infect Immun; 1986 Dec; 54(3):742-50. PubMed ID: 3536747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.
    Small JM; Mitchell TG
    Infect Immun; 1989 Dec; 57(12):3751-6. PubMed ID: 2680980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis.
    Kozel TR; Mastroianni RP
    Infect Immun; 1976 Jul; 14(1):62-7. PubMed ID: 780279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages.
    Swenson FJ; Kozel TR
    Infect Immun; 1978 Sep; 21(3):714-20. PubMed ID: 361575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
    Laxalt KA; Kozel TR
    Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation of a hydrophobic surface from phagocytosis of encapsulated and non-encapsulated cryptococcus neoformans.
    Kozel TR
    Infect Immun; 1983 Mar; 39(3):1214-9. PubMed ID: 6341232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the capsule in phagocytosis of Cryptococcus neoformans.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
    Young BJ; Kozel TR
    Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.
    Collins HL; Bancroft GJ
    Infect Immun; 1991 Nov; 59(11):3883-8. PubMed ID: 1937747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.
    Schlageter AM; Kozel TR
    Infect Immun; 1990 Jun; 58(6):1914-8. PubMed ID: 2187813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
    Eckert TF; Kozel TR
    Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular fate of Cryptococcus neoformans.
    Tacker JR; Farhi F; Bulmer GS
    Infect Immun; 1972 Aug; 6(2):162-7. PubMed ID: 4569916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Infect Immun; 1988 Nov; 56(11):2794-800. PubMed ID: 3049374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.